CoChat

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A

Open access

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

It is essential to improve therapies for controlling excessive bleeding in patients with haemorrhagic disorders. As activated blood platelets mediate the primary response to vascular injury, we hypothesize that storage of coagulation Factor VIII within platelets may provide a locally inducible treatment to maintain haemostasis for haemophilia A. Here we show that haematopoietic stem cell gene therapy can prevent the occurrence of severe bleeding episodes in dogs with haemophilia A for at least 2.5 years after transplantation. We employ a clinically relevant strategy based on a lentiviral vector encoding the ITGA2B gene promoter, which drives platelet-specific expression of human FVIII permitting storage and release of FVIII from activated platelets. One animal receives a hybrid molecule of FVIII fused to the von Willebrand Factor propeptide-D2 domain that traffics FVIII more effectively into α-granules. The absence of inhibitory antibodies to platelet-derived FVIII indicates that this approach may have benefit in patients who reject FVIII replacement therapies. Thus, platelet FVIII may provide effective long-term control of bleeding in patients with haemophilia A.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms3773

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Platelet-targeted lentiviral vector design. (a) ITGA2B gene promoter fragments direct megakaryocyte-specific expression in luciferase reporter assay. Human pro-megakaryocytic, lymphocytic, erythrocytic and epithelial cell lines are transfected with a luciferase reporter construct under the control of one of three fragments of the human ITGA2B gene promoter beginning at either nucleotide −1218(green), −889(yellow) or −673(red) in-frame with the luciferase gene. A luciferase construct without a gene promoter served as a negative (−)control (peach), whereas a construct with a tissue-nonspecific gene promoter of the cytomegalovirus (CMV) is a positive (+)control (blue) arbitrarily assigned a value of 100% luciferase activity. Lysates of each cell line (x axis) were measured in duplicate on a luminometer to report the percent (%) luciferase activity (y axis) for each construct within each cell line. Cells were co-transfected with plasmid constructs encoding the marker gene, β-galactosidase, under the under the control of the CMV promoter to correct for variations in transfection efficiency. Shown is one representative of nine experiments where the error bars represent the s.d. from the mean value of measurements made in duplicate. (b) −889ITGA2B-BDDFVIII-WPTS lentiviral vector diagram. Shown is the region between the 5′-long terminal repeat (LTR) (left, blue box) and 3′-LTR without a U3 enhancer/promoter (right, blue box) to permit the ITGA2B promoter (yellow arrow) to direct megakaryocyte-specific synthesis of BDDFVIII (grey circle). The −889ITGA2B promoter binds GATA and Ets transcription factors for high-level gene expression in megakaryocytes and a repressor region inhibits gene expression in other lineages (yellow arrow). The central polypurine tract (cPPT, navy) and woodchuck hepatitis virus postregulatory element (WPRE, purple diamond) enhance efficiency of transgene expression. (c) −673ITGA2B-VWFSPD2-BDDFVIII-WPTS lentiviral vector diagram. The backbone of this vector is the same as described in b, except a smaller −673ITGA2B promoter (red arrow) was fused to DNA encoding the human VWF signal peptide (SP) and D2 domain (peach circle) to traffic BDDFVIII (grey circle) directly to platelet α–granules.
Figure 1 Platelet-targeted lentiviral vector design. (a) ITGA2B gene promoter fragments direct megakaryocyte-specific expression in luciferase reporter assay. Human pro-megakaryocytic, lymphocytic, erythrocytic and epithelial cell lines are transfected with a luciferase reporter construct under the control of one of three fragments of the human ITGA2B gene promoter beginning at either nucleotide −1218(green), −889(yellow) or −673(red) in-frame with the luciferase gene. A luciferase construct without a gene promoter served as a negative (−)control (peach), whereas a construct with a tissue-nonspecific gene promoter of the cytomegalovirus (CMV) is a positive (+)control (blue) arbitrarily assigned a value of 100% luciferase activity. Lysates of each cell line (x axis) were measured in duplicate on a luminometer to report the percent (%) luciferase activity (y axis) for each construct within each cell line. Cells were co-transfected with plasmid constructs encoding the marker gene, β-galactosidase, under the under the control of the CMV promoter to correct for variations in transfection efficiency. Shown is one representative of nine experiments where the error bars represent the s.d. from the mean value of measurements made in duplicate. (b) −889ITGA2B-BDDFVIII-WPTS lentiviral vector diagram. Shown is the region between the 5′-long terminal repeat (LTR) (left, blue box) and 3′-LTR without a U3 enhancer/promoter (right, blue box) to permit the ITGA2B promoter (yellow arrow) to direct megakaryocyte-specific synthesis of BDDFVIII (grey circle). The −889ITGA2B promoter binds GATA and Ets transcription factors for high-level gene expression in megakaryocytes and a repressor region inhibits gene expression in other lineages (yellow arrow). The central polypurine tract (cPPT, navy) and woodchuck hepatitis virus postregulatory element (WPRE, purple diamond) enhance efficiency of transgene expression. (c) −673ITGA2B-VWFSPD2-BDDFVIII-WPTS lentiviral vector diagram. The backbone of this vector is the same as described in b, except a smaller −673ITGA2B promoter (red arrow) was fused to DNA encoding the human VWF signal peptide (SP) and D2 domain (peach circle) to traffic BDDFVIII (grey circle) directly to platelet α–granules.CC BY · PubMed Central
Figure 2 Synthesis and trafficking of BDDFVIII into canine platelet α-granules. (a) Confocal microscopy showing co-localization of BDDFVIII and Fg within platelets. Canine CD34+G-PBC were transduced with lentivirions encoding human BDDFVIII followed by transplant haemophilia A dogs. Peripheral blood platelets were isolated from whole blood, fixed, permeabilized and examined by indirect immunofluorescence analysis for Fg and BDDFVIII distribution. Shown is a representative image using a × 10 eye piece and × 100 oil objective and a × 2 digital zoom of platelets isolated from one transplanted animal (I42) from an experiment that was performed seven times on all three dogs and a FVIII-deficient negative control. Fg was visualized with a 1°Ab to this platelet-specific marker for α-granules and a Alexa488-conjugated 2°Ab (left, green). BDDFVIII was detected with 1°Ab to human FVIII and an Alexa568-conjugated 2°Ab (middle, red). BDDFVIII colocalized with Fg is observed when the two images are merged (right, yellow). The white scale bar is 5 μm in length. (b) Electron microscopy localized human BDDFVIII directly in α-granules. Shown is a representative image of BDDFVIII absent from an ultrathin cryosection of a single platelet α-granule (blue arrow) from a FVIII-deficient (negative control, F26) when probed with a 1°Ab (301.3) to human BDDFVIII and a 2°Ab-conjugated to 10-nm gold particles. In contrast, BDDFVIII was localized directly within the α-granule (red arrow) and within intracytoplasmic membrane systems (yellow arrow) in representative images from all three experimental dogs (F20, I42 and M64). Interestingly, sections from dog (M64) receiving the −673ITGA2B-VWFSPD2-BDDFVIII-transduced G-PBC (VWF-targeting peptide) exhibited a noticably higher concentration of BDDFVIII within mature platelet α-granules. Each sample was cut on a minimum of three separate occasions with a series of ultrathin sections subjected to immunogold labelling and analysis of at least 100 α-granules per sample. The white scale bar is 0.2 μm in length.
Figure 2 Synthesis and trafficking of BDDFVIII into canine platelet α-granules. (a) Confocal microscopy showing co-localization of BDDFVIII and Fg within platelets. Canine CD34+G-PBC were transduced with lentivirions encoding human BDDFVIII followed by transplant haemophilia A dogs. Peripheral blood platelets were isolated from whole blood, fixed, permeabilized and examined by indirect immunofluorescence analysis for Fg and BDDFVIII distribution. Shown is a representative image using a × 10 eye piece and × 100 oil objective and a × 2 digital zoom of platelets isolated from one transplanted animal (I42) from an experiment that was performed seven times on all three dogs and a FVIII-deficient negative control. Fg was visualized with a 1°Ab to this platelet-specific marker for α-granules and a Alexa488-conjugated 2°Ab (left, green). BDDFVIII was detected with 1°Ab to human FVIII and an Alexa568-conjugated 2°Ab (middle, red). BDDFVIII colocalized with Fg is observed when the two images are merged (right, yellow). The white scale bar is 5 μm in length. (b) Electron microscopy localized human BDDFVIII directly in α-granules. Shown is a representative image of BDDFVIII absent from an ultrathin cryosection of a single platelet α-granule (blue arrow) from a FVIII-deficient (negative control, F26) when probed with a 1°Ab (301.3) to human BDDFVIII and a 2°Ab-conjugated to 10-nm gold particles. In contrast, BDDFVIII was localized directly within the α-granule (red arrow) and within intracytoplasmic membrane systems (yellow arrow) in representative images from all three experimental dogs (F20, I42 and M64). Interestingly, sections from dog (M64) receiving the −673ITGA2B-VWFSPD2-BDDFVIII-transduced G-PBC (VWF-targeting peptide) exhibited a noticably higher concentration of BDDFVIII within mature platelet α-granules. Each sample was cut on a minimum of three separate occasions with a series of ultrathin sections subjected to immunogold labelling and analysis of at least 100 α-granules per sample. The white scale bar is 0.2 μm in length.CC BY · PubMed Central
Figure 3 Quantitative analysis of platelet FVIII. Flow cytometric analysis of platelets. BDDFVIII was absent in platelets (x axis) analysed from a FVIII-deficient dog used as a negative control for staining with a human BDDFVIII 1°Ab and Alexa Fluor 568-conjugated 2°Ab (black, unshaded histogram). In contrast G-PBC from transplanted dogs displayed appreciable levels of platelet BDDFVIII (shaded histogram: −889ITGA2B-driven FVIII of F20 and I42, yellow; −673ITGA2B-driven FVIII of M64, red). The hierarchy for the mean fluorescence intensity of FVIII expression reveals that F20<I42<M64. Shown are the results from one experiment analysis of 50,000 platelets per sample at 2.9 (F20), 1.9 (I42) and 0.9 (M64) years after infusion of FVIII-transduced G-PBC, which is representative of the outcome of seven separate experiments.
Figure 3 Quantitative analysis of platelet FVIII. Flow cytometric analysis of platelets. BDDFVIII was absent in platelets (x axis) analysed from a FVIII-deficient dog used as a negative control for staining with a human BDDFVIII 1°Ab and Alexa Fluor 568-conjugated 2°Ab (black, unshaded histogram). In contrast G-PBC from transplanted dogs displayed appreciable levels of platelet BDDFVIII (shaded histogram: −889ITGA2B-driven FVIII of F20 and I42, yellow; −673ITGA2B-driven FVIII of M64, red). The hierarchy for the mean fluorescence intensity of FVIII expression reveals that F20<I42<M64. Shown are the results from one experiment analysis of 50,000 platelets per sample at 2.9 (F20), 1.9 (I42) and 0.9 (M64) years after infusion of FVIII-transduced G-PBC, which is representative of the outcome of seven separate experiments.CC BY · PubMed Central
Figure 4 Activated platelets induced to secrete FVIII:C. To detect FVIII:C activity present in lysate of quiescent, untreated platelets (black circle; (−) agonist) and FVIII:C activity remaining in lysate after secretion of BDDFVIII from platelets treated with a mixture of physiological agonists of platelet activation: ADP, epinephrine and canine PAR1,3,4 (white circle: (+) agonist). Platelet lysates from a FVIII-deficient negative control dog show that the level of FVIII:C background activity is virtually unchanged for untreated and activated platelets. Dogs that received BDDFVIII-transduced G-PBC show an appreciable decrease in FVIII:C activity only after platelet activation; thus demonstrating that platelets isolated from experimental dogs can be induced to secrete FVIII. Each data point represents the mean value of FVIII:C activity from two independent samples each measured in duplicate with s.d. represented by black error bars. Shown is the result from one experiment performed at 2.7 (F20), 1.6 (I42) and 0.6 (M64) years after infusion of FVIII-transduced G-PBC, which is representative of the outcome of three separate experiments.
Figure 4 Activated platelets induced to secrete FVIII:C. To detect FVIII:C activity present in lysate of quiescent, untreated platelets (black circle; (−) agonist) and FVIII:C activity remaining in lysate after secretion of BDDFVIII from platelets treated with a mixture of physiological agonists of platelet activation: ADP, epinephrine and canine PAR1,3,4 (white circle: (+) agonist). Platelet lysates from a FVIII-deficient negative control dog show that the level of FVIII:C background activity is virtually unchanged for untreated and activated platelets. Dogs that received BDDFVIII-transduced G-PBC show an appreciable decrease in FVIII:C activity only after platelet activation; thus demonstrating that platelets isolated from experimental dogs can be induced to secrete FVIII. Each data point represents the mean value of FVIII:C activity from two independent samples each measured in duplicate with s.d. represented by black error bars. Shown is the result from one experiment performed at 2.7 (F20), 1.6 (I42) and 0.6 (M64) years after infusion of FVIII-transduced G-PBC, which is representative of the outcome of three separate experiments.CC BY · PubMed Central
Figure 5 PCR analysis for detection and localization of lentiviral vector within canine genome. (a) Long-term detection of BDDFVIII-lentiviral vector within leukocyte genomic DNA. Shown is an ethidium bromide-stained agarose gel of PCR product-derived genomic DNA isolated from canine peripheral blood leukocytes. Molecular weight markers (Lane 1) are labelled on the left in base pairs (bp). In Lane 2, p−889ITGA2B-BDDFVIII-WPTS served as a positive control for PCR of a 302 bp region of the lentiviral WPRE. PCR failed to detect WPRE within leukocyte genomic DNA from a FVIII-deficient dog serving as a negative control (Lane 3). In contrast, WPRE was detected in the PCR of all three experimental dogs (F20, I42, M64; Lanes 4–6) for at least 2.5 years after G-PBC transplant demonstrating long-term insertion of the lentiviral vector into the canine genome. All reactions were run in triplicate from at least three separate samples collected periodically for at least 2.5 years after G-PBC transplant. (b) Linear amplification-mediated (LAM)-PCR to localize lentiviral vector within canine genome. Polyacrylamide gel of LAM-PCR products from a FVIII-deficient negative control and experimental dogs at 2.5 (F20), 1.4 (I42) and 0.5 (M64) years after infusion of FVIII-transduced G-PBC. PCR was performed on genomic DNA isolated from leukocytes purified with Ficoll from circulating peripheral blood. Each amplified band represents a distinct proviral integration. All lanes appear to contain multiple insertions, indicative of polyclonality. The panel underwent black–white inversion from the original digital image, and levels were globally adjusted to improve visibility of all bands. DNA standard markers (Lane 1 and 6) labelled on left in base pairs.
Figure 5 PCR analysis for detection and localization of lentiviral vector within canine genome. (a) Long-term detection of BDDFVIII-lentiviral vector within leukocyte genomic DNA. Shown is an ethidium bromide-stained agarose gel of PCR product-derived genomic DNA isolated from canine peripheral blood leukocytes. Molecular weight markers (Lane 1) are labelled on the left in base pairs (bp). In Lane 2, p−889ITGA2B-BDDFVIII-WPTS served as a positive control for PCR of a 302 bp region of the lentiviral WPRE. PCR failed to detect WPRE within leukocyte genomic DNA from a FVIII-deficient dog serving as a negative control (Lane 3). In contrast, WPRE was detected in the PCR of all three experimental dogs (F20, I42, M64; Lanes 4–6) for at least 2.5 years after G-PBC transplant demonstrating long-term insertion of the lentiviral vector into the canine genome. All reactions were run in triplicate from at least three separate samples collected periodically for at least 2.5 years after G-PBC transplant. (b) Linear amplification-mediated (LAM)-PCR to localize lentiviral vector within canine genome. Polyacrylamide gel of LAM-PCR products from a FVIII-deficient negative control and experimental dogs at 2.5 (F20), 1.4 (I42) and 0.5 (M64) years after infusion of FVIII-transduced G-PBC. PCR was performed on genomic DNA isolated from leukocytes purified with Ficoll from circulating peripheral blood. Each amplified band represents a distinct proviral integration. All lanes appear to contain multiple insertions, indicative of polyclonality. The panel underwent black–white inversion from the original digital image, and levels were globally adjusted to improve visibility of all bands. DNA standard markers (Lane 1 and 6) labelled on left in base pairs.CC BY · PubMed Central
Figure 6 Correction of the canine haemophilia A phenotype with platelet BDDFVIII. A Coatest SP4 FVIII chromagenic analysis assay was performed on lysates of 1 × 108 washed peripheral blood platelets resuspended in 1 ml of lysis buffer from samples collected periodically for at least 2.5 years after transplant (x axis). The mean value of FVIII activity (mU ml per 108 platelets) is represented by the plotting of data points recorded from two independent samples (each measured in duplicate) with error bars showing ±s.d. for at least 12 time points (y axis). Analysis of platelet FVIII:C activity from a FVIII-deficient dog served as a negative control (black, solid line). Interestingly, the level of FVIII:C activity was detected above background levels at regular intervals (blue dashed line) for ≈2.5 years after transplant of BDDFVIII-transduced G-PBC (F20, top; I42, middle; M64, bottom panel). Note, each dog was administered daily injections of FVIII in the form of canine blood transfusions or cFVIII (red bracket) and EACA (green bracket) for uncontrolled bleeding for a short time after transplant (until haemocult tests were negative). As anticipated, each dogs required cFVIII supplements (red arrows) to help resolve severe bleeding episodes incurred before G-PBC transplant. Remarkably, only F20 (which had the lowest steady state level of FVIII:C activity) required cFVIII supplements after G-PBC transplant demonstrating platelet FVIII:C activity reached therapeutic levels in I42 and M64.
Figure 6 Correction of the canine haemophilia A phenotype with platelet BDDFVIII. A Coatest SP4 FVIII chromagenic analysis assay was performed on lysates of 1 × 108 washed peripheral blood platelets resuspended in 1 ml of lysis buffer from samples collected periodically for at least 2.5 years after transplant (x axis). The mean value of FVIII activity (mU ml per 108 platelets) is represented by the plotting of data points recorded from two independent samples (each measured in duplicate) with error bars showing ±s.d. for at least 12 time points (y axis). Analysis of platelet FVIII:C activity from a FVIII-deficient dog served as a negative control (black, solid line). Interestingly, the level of FVIII:C activity was detected above background levels at regular intervals (blue dashed line) for ≈2.5 years after transplant of BDDFVIII-transduced G-PBC (F20, top; I42, middle; M64, bottom panel). Note, each dog was administered daily injections of FVIII in the form of canine blood transfusions or cFVIII (red bracket) and EACA (green bracket) for uncontrolled bleeding for a short time after transplant (until haemocult tests were negative). As anticipated, each dogs required cFVIII supplements (red arrows) to help resolve severe bleeding episodes incurred before G-PBC transplant. Remarkably, only F20 (which had the lowest steady state level of FVIII:C activity) required cFVIII supplements after G-PBC transplant demonstrating platelet FVIII:C activity reached therapeutic levels in I42 and M64.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

Metadata

Authors
Du, L. M., Nurden, P., Nurden, A. T., Nichols, T. C., Bellinger, D. A., Jensen, E. S., Haberichter, S. L., Merricks, E., Raymer, R. A., Fang, J., Koukouritaki, S. B., Jacobi, P. M., Hawkins, T. B., Cornetta, K., Shi, Q., & Wilcox, D. A.
Affiliations
  • Children's Hospital of Wisconsin (US)
  • Electrophysiology and Heart Modeling Institute (FR)
  • University of North Carolina at Chapel Hill (US)
  • Versiti Blood Center of Wisconsin (US)
  • Indiana University Indianapolis (US)
Corresponding author
Wilcox, David A.
Venue
Nature Communications
Published
2013-11-19
Volume
4
Issue
1
Pages
2773-2773
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2039928766
Cited by
119
References
59
Citations by year
2025: 5 · 2024: 4 · 2023: 11 · 2022: 11 · 2021: 9 · 2020: 9 · 2019: 6 · 2018: 9 · 2017: 7 · 2016: 14 · 2015: 21 · 2014: 11 · 2013: 2
FWCI
11.48
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • UNC Libraries
Funders
  • American Heart Association
  • Medical College of Wisconsin
  • Children’s Hospital of Wisconsin Research Institute
  • Children's Hospital Foundation
  • Agence Nationale de la Recherche (ANR-08-GENO-028-03)
  • Institut National de la Santé et de la Recherche Médicale (ANR-08-GENO-028-03)
  • National Institutes of Health (HL-68138, HL63098)
  • University of North Carolina at Chapel Hill
  • National Heart, Lung, and Blood Institute (HL-102035, P40HL116242, HL 68138, R24HL063098, R01HL068138, HL-63 098, R01HL102035)
Topics
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
hemophilia A, factor VIII, hemostasis, lentiviral vectors, platelet alpha-granules, factor VIII inhibitors, dogs, hemorrhage control
MeSH terms
Animals, Blood Platelets, Dog Diseases, Dogs, Factor VIII, Gene Expression Regulation, Hemophilia A, Hemostasis, Humans, Genetic Therapy, Integrin alpha2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.